All Stories

  1. Possible involvement of keratinocyte‐derived microvesicle particles in human photosensitivity disorders
  2. The Biological Effects of Soy Isoflavones against Myocardial Ischemia-reperfusion Injuries: A Systematic Review
  3. Pharmacokinetic profiles of sertraline in pregnancy as a predictor of postpartum depressive symptoms
  4. Possible involvement of keratinocyte-derived microvesicle particles in human photosensitivity disorders
  5. The Effects of Resveratrol on Menopausal Cardio-metabolic Changes: A Systematic Review
  6. A Novel Maturation Equation for Hepatic Clearance Across Preterm, Term Neonates, Children, and Adults: Application to Paracetamol and Its Metabolite
  7. Anti-Cancer Effects of Soy Isoflavones against Cancer by Radiosensitizing Properties: A Systematic Review
  8. The Relationship between Statin Intake and Risk of Pancreatic Cancer: A Systematic Review and Meta-analysis
  9. Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review
  10. Modernizing Preclinical Drug Development: The Role of New Approach Methodologies
  11. Vancomycin dosing in neonates: enhancing outcomes using population pharmacokinetics and simulation
  12. The Association between Gallstone Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis
  13. The Biological Effects of Nano-Curcumins against Drugs and Chemicals-Induced Nephrotoxicity: A Systematic Review
  14. Chrysin and Bone Health: A Systematic Review of its Role in Bone Regeneration, Density, and Mass Enhancement
  15. Mechanistic Effects and Complications of Berberine on Cardiac Arrhythmias: A Systematic Review
  16. The Special Issue “The 20th Anniversary of Pharmaceuticals—Multi-Targeted Natural Products as Therapeutics” Editorial—Multi-Targeted Therapeutics from Natural Sources: What Do We Know?
  17. Advances in Radiation Therapy Enhancement and Radio-Protection By Nano-Curcumins: A Systematic Review
  18. Pharmacokinetic effect of disease severity and use of extracorporeal membrane oxygenation in critically ill Asian patients receiving vancomycin
  19. The Association between use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis
  20. Prediction of lacosamide concentrations to support dose optimization during pregnancy
  21. Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review
  22. Association Between Gallstone Disease and Kidney Stone Disease: A Systematic Review and Meta-analysis
  23. The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies
  24. Efficacy and Mechanisms of Silybum Marianum, Silymarin, and Silibinin on Rheumatoid Arthritis and Osteoarthritis Symptoms: A Systematic Review
  25. The Association between Statins Intake and Risk of Post Stroke Pneumonia: A Systematic Review and Meta-Analysis
  26. A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer
  27. Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review
  28. The Therapeutic Effects of Bromelain against Colorectal Cancer: A Systematic Review
  29. When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers?
  30. Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis
  31. The Analgesic Effect of Ginger on Postoperative Pain: A Systematic Review of Clinical Trials
  32. Association Between Gallstone Disease and Risk of Mortality of Cardiovascular Disease and Cancer: A Systematic Review and Meta-Analysis
  33. Effects of Curcuma longa (turmeric) and curcumin on the premenstrual syndrome and dysmenorrhea: A systematic review
  34. A physiological approach to renal clearance: From premature neonates to adults
  35. The survey of antitumor effects of bromelain on neoplastic breast cells: A systematic review
  36. Effect and Mechanism of Curcumin on Bone Loss and Osteoporosis: A Systematic Review
  37. Neuroprotective Effects of Bromelain on the Common Neurodegenerative Diseases: A Systematic Review
  38. A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer
  39. Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia
  40. Editorial: Genetics and ontogeny in precision therapeutics for children
  41. Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats
  42. A perspective on In vitro developmental neurotoxicity test assay results: An expert panel review
  43. The Role of Vitamin D in Carpal Tunnel Syndrome Risk and Supplementation Outcomes: A Systematic Review
  44. Effect of Curcumin on Oxidative Stress, Inflammatory Response and Kidney Biochemical Parameters Among Kidney Disease Patients: A Systematic Review
  45. Pharmacokinetics and safety of prolonged paracetamol treatment in neonates: An interventional cohort study
  46. Topical Photodynamic Therapy Generates Bioactive Microvesicle Particles: Evidence for a Pathway Involved in Immunosuppressive Effects
  47. The Effect of Inhalation Aromatherapy on Patients with Cardiovascular Disease Seeking Pain Relief: A Systematic Review and Meta-analysis
  48. Editorial: Methods and protocols in obstetric and pediatric pharmacology: 2022
  49. Editorial: Women in obstetric and pediatric pharmacology: 2021
  50. Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents
  51. Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure
  52. Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders
  53. Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis
  54. Editorial: Publishing in 2023 and Beyond
  55. Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade
  56. Pharmacokinetics of l-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension
  57. Exploring the Past to Inform the Future to Optimize the Pharmacokinetics of Vancomycin in Children With Severe Burn Injuries
  58. Optimal dosing of enoxaparin in overweight and obese children
  59. Relationship between serum vitamin D and hip fracture in the elderly: a systematic review and meta-analysis
  60. Effectiveness of phosphodiesterase type 5 inhibitors on the treatment of thin endometrium and pregnancy outcomes: An systematic review
  61. Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children
  62. Effects and Mechanisms of Medicinal Plants on Healing Scars: A Systematic Review
  63. Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources?
  64. Evidence for Systemic Reactive Oxygen Species in UVB‐mediated Microvesicle Formation
  65. Effects of Medicinal Plants on Human Hosts and Zoonotic Helminthic Infections: A Systematic Review
  66. Maternal Exposure and Neonatal Effects of Drugs of Abuse
  67. Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity
  68. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients
  69. Oral drug dosing following bariatric surgery: General concepts and specific dosing advice
  70. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
  71. Effects of a new thyrotropic drug isolated from Potentilla alba on the male reproductive system of rats and offspring development
  72. Creatinine‐Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs
  73. How can we improve the safe use of herbal medicine and other natural products? A clinical pharmacologist mission
  74. Population pharmacokinetics of olanzapine in children
  75. Spotlight Commentary: Why we need to pay attention to toxicity associated with herbal medicines
  76. Supportive care medications coinciding with chemotherapy among children with hematologic malignancy
  77. Investigation into the reproducibility of the association of cord blood magnesium concentration and cerebral palsy or death in children
  78. The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease
  79. Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review
  80. Use of Herbal Medicine by Pregnant Women: What Physicians Need to Know
  81. Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals
  82. Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches
  83. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
  84. Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis
  85. Development of a neonatal adverse event severity scale through a Delphi consensus approach
  86. Population Pharmacokinetic Modeling of Gentamicin in Pediatrics
  87. Generic drug products in paediatrics: Where are the data?
  88. Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+
  89. Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates
  90. Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates
  91. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus
  92. Renal Clearance in Newborns and Infants: Predictive Performance of Population‐Based Modeling for Drug Development
  93. Cost‐effectiveness of early cancer surveillance for patients with Li–Fraumeni syndrome
  94. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children
  95. The effect of a prescription order requirement for pharmacist-administered vaccination on herpes zoster vaccination rates
  96. Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
  97. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus
  98. Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study
  99. Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma
  100. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis
  101. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
  102. The clinical utility of pharmacometric models
  103. Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset
  104. Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study
  105. Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses
  106. Inclusion of pregnant and breastfeeding women in research - efforts and initiatives
  107. Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model
  108. The Need for Pediatric Drug Development
  109. Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance
  110. Riding (High) into the danger zone: a review of potential differences in chemical exposures in fighter pilots resulting from high altitude and G-forces
  111. Can ad hoc analyses of clinical trials help personalize treatment decisions?
  112. Population Pharmacokinetic Model of Transdermal Nicotine Delivered from a Matrix-Type Patch
  113. The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies
  114. Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin
  115. Analgesics commonly used to treat pediatric patients with malignancy.
  116. Use of TEG/Platelet Mapping to Dose-Adjust Platelet Inhibitors in Children Supported with the Berlin EXCOR: In Search of a Correlation
  117. Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma
  118. Hepatic Drug Metabolism in Pediatric Patients
  119. Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide
  120. Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma
  121. A Retrospective Study of the Impact of Rapid Diagnostic Testing on Time to Pathogen Identification and Antibiotic Use for Children with Positive Blood Cultures
  122. Herbal medicines: challenges in the modern world. Part 4. Canada and United States
  123. Newborns still lack drug data to guide therapy
  124. Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding
  125. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections
  126. AUC‐Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis
  127. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus
  128. Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics
  129. Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler
  130. Herbal medicines: challenges in the modern world. Part 3. China and Japan
  131. Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
  132. Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial
  133. Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy
  134. Unanswered Questions Regarding Optimal Pediatric Vancomycin Use
  135. Herbal medicines: challenges in the modern world. Part 2. European Union and Russia
  136. Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children
  137. Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent–Metabolite Population Pharmacokinetic Model
  138. Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand
  139. Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children
  140. Comparison of the New Adult Ventilator-Associated Event Criteria to the Centers for Disease Control and Prevention Pediatric Ventilator-Associated Pneumonia Definition (PNU2) in a Population of Pediatric Traumatic Brain Injury Patients*
  141. Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care
  142. Therapeutic Drug Monitoring in Pregnancy
  143. Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites
  144. Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?
  145. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
  146. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration–Time Curve to the Minimum Inhibitory Concentration ≥400 Target
  147. Pharmacokinetic considerations in the use of antivirals in neonates
  148. Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens
  149. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates
  150. A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults
  151. Challenges Associated with Route of Administration in Neonatal Drug Delivery
  152. Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone
  153. Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation
  154. Pharmacokinetic modeling of therapies for systemic lupus erythematosus
  155. National Trends in the Incidence, Outcomes and Charges of Pediatric Osteoarticular Infections, 1997–2012
  156. Economic Analysis of Rapid and Sensitive Polymerase Chain Reaction Testing in the Emergency Department for Influenza Infections in Children
  157. Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC–MS-MS
  158. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates
  159. Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial
  160. Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
  161. Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data
  162. Special population considerations and regulatory affairs for clinical research
  163. Clinical Pharmacokinetics of Inhaled Antimicrobials
  164. How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-based detection
  165. Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies
  166. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis
  167. Relationship Between Zolpidem Concentrations and Sleep Parameters in Pediatric Burn Patients
  168. Outpatient Parenteral Antimicrobial Therapy in Pediatrics: An Opportunity to Expand Antimicrobial Stewardship
  169. An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia
  170. Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature
  171. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection
  172. Levofloxacin inhalation solution for the treatment of chronicPseudomonas aeruginosainfection among patients with cystic fibrosis
  173. Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring
  174. Neonatal Magnesium Levels Correlate with Motor Outcomes in Premature Infants: A Long-Term Retrospective Cohort Study
  175. Illustrative neonatal cases regarding drug delivery issues
  176. Ethics of Drug Studies in the Newborn
  177. Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections
  178. Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia
  179. Intrapartum Magnesium Sulfate and the Potential for Cardiopulmonary Drug–Drug Interactions
  180. Appropriate prescribing for acute childhood infections
  181. Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin
  182. Preliminary Assessment of Zolpidem Pharmacokinetics in Pediatric Burn Patients
  183. Pharmacokinetics and Pharmacodynamics of Antibacterials, Antifungals, and Antivirals Used Most Frequently in Neonates and Infants
  184. Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration
  185. Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
  186. Amikacin population pharmacokinetics among paediatric burn patients
  187. Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations
  188. Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999–2012
  189. Utilization of Optimal Study Design for Maternal and Fetal Sheep Propofol Pharmacokinetics Study: A Preliminary Study
  190. Intravenous drug delivery in neonates: lessons learnt
  191. Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity
  192. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
  193. Maternal Magnesium Sulphate Exposure Predicts Neonatal Magnesium Blood Concentrations
  194. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis
  195. Absence of P-Glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat
  196. Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov
  197. Considerations in the Pharmacologic Treatment and Prevention of Neonatal Sepsis
  198. A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates
  199. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
  200. Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov
  201. Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis
  202. Invasive Pneumococcal Disease in Infants Younger Than 90 Days Before and After Introduction of PCV7
  203. Variability of Histamine Pharmacodynamic Response in Children With Allergic Rhinitis
  204. Seasonality of Acute Otitis Media and the Role of Respiratory Viral Activity in Children
  205. Prevalence of nematode infection and faecal egg counts in free-range laying hens: relations to housing and husbandry
  206. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
  207. Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry
  208. Population Pharmacokinetic Modeling of Risperidone and 9-Hydroxyrisperidone to Estimate CYP2D6 Subpopulations in Children and Adolescents
  209. Metabolic and toxicological considerations for sepsis drug treatments
  210. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
  211. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
  212. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
  213. Fundamentals of Population Pharmacokinetic Modelling
  214. Fundamentals of Population Pharmacokinetic Modelling
  215. Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
  216. Fundamentals of Population Pharmacokinetic Modelling
  217. Fundamentals of Population Pharmacokinetic Modelling
  218. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood‐onset systemic lupus erythematosus
  219. The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era
  220. Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance
  221. Population Pharmacokinetic and Pharmacodynamic Modeling of High-Dose Intermittent Ticarcillin-Clavulanate Administration in Pediatric Cystic Fibrosis Patients
  222. Pharmacokinetics of Prednisolone at Steady State in Young Patients With Systemic Lupus Erythematosus on Prednisone Therapy: An Open-Label, Single-Dose Study
  223. Pharmacokinetics of Levetiracetam in Neonates with Seizures
  224. Optimal study design for pioglitazone in septic pediatric patients
  225. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus
  226. The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease
  227. Individualised dosing of amikacin in neonates
  228. Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates
  229. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates
  230. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates
  231. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis
  232. Utility of Interleukin-12 and Interleukin-10 in Comparison with Other Cytokines and Acute-Phase Reactants in the Diagnosis of Neonatal Sepsis
  233. Individualising netilmicin dosing in neonates
  234. A simple binding assay for the direct determination of biotin in urine
  235. Medication Exposures During Pregnancy and Breastfeeding